Targeted mitochondrial genome elimination

Sandra R. Bacman, Claudia V. Pereira, Carlos T Moraes

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Mitochondrial diseases are a heterogeneous group of pathologies, presenting mitochondrial oxidative phosphorylation (OXPHOS) deficiency and subsequent deterioration of affected tissues, usually the ones with high energy demand. Nuclear and mitochondrial DNA (mtDNA) mutations have been associated with mitochondrial disorders, and only palliative therapies are available, with no approach available to correct the underlining genetic problem. Our and other groups, taking advantage of mtDNA heteroplasmy, were able to develop gene therapy strategies to target the mtDNA, inducing the increase of the wild-type haplotype. The gene editing tools used by our group and others such as specific endonucleases targeted to the mitochondria, and more recently mitoTALENs and mitochondrial Zinc-Finger Nucleases were shown to effectively shift mtDNA heteroplasmy. This change towards an increase in wild-type mtDNA molecules occurred when the nuclease was specifically designed to cleave DNA regions harboring point mutations or the common deletion. In this chapter we will focus on strategies to target specific mtDNA haplotypes to shift heteroplasmy in vitro and in vivo. A brief overview on heteroplasmic animal models and viral delivery will be introduced, as these will be critical for future translation of this approach into human gene therapy.

Original languageEnglish (US)
Title of host publicationMitochondrial Biology and Experimental Therapeutics
PublisherSpringer International Publishing
Pages535-563
Number of pages29
ISBN (Electronic)9783319733449
ISBN (Print)9783319733432
DOIs
StatePublished - Mar 21 2018

Fingerprint

Mitochondrial Genome
Mitochondrial DNA
Genes
Mitochondrial Diseases
Gene therapy
Genetic Therapy
Haplotypes
Mitochondria
Endonucleases
Zinc Fingers
Pathology
Palliative Care
Point Mutation
Deterioration
Zinc
Animals
Animal Models
Tissue
Mutation
Molecules

Keywords

  • DNA editing
  • Gene therapy
  • Heteroplasmy
  • Mitochondrial diseases
  • mtDNA
  • TALEN

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bacman, S. R., Pereira, C. V., & Moraes, C. T. (2018). Targeted mitochondrial genome elimination. In Mitochondrial Biology and Experimental Therapeutics (pp. 535-563). Springer International Publishing. https://doi.org/10.1007/978-3-319-73344-9_24

Targeted mitochondrial genome elimination. / Bacman, Sandra R.; Pereira, Claudia V.; Moraes, Carlos T.

Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing, 2018. p. 535-563.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bacman, SR, Pereira, CV & Moraes, CT 2018, Targeted mitochondrial genome elimination. in Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing, pp. 535-563. https://doi.org/10.1007/978-3-319-73344-9_24
Bacman SR, Pereira CV, Moraes CT. Targeted mitochondrial genome elimination. In Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing. 2018. p. 535-563 https://doi.org/10.1007/978-3-319-73344-9_24
Bacman, Sandra R. ; Pereira, Claudia V. ; Moraes, Carlos T. / Targeted mitochondrial genome elimination. Mitochondrial Biology and Experimental Therapeutics. Springer International Publishing, 2018. pp. 535-563
@inbook{7216cea79f634dd1a903a34da3bcb624,
title = "Targeted mitochondrial genome elimination",
abstract = "Mitochondrial diseases are a heterogeneous group of pathologies, presenting mitochondrial oxidative phosphorylation (OXPHOS) deficiency and subsequent deterioration of affected tissues, usually the ones with high energy demand. Nuclear and mitochondrial DNA (mtDNA) mutations have been associated with mitochondrial disorders, and only palliative therapies are available, with no approach available to correct the underlining genetic problem. Our and other groups, taking advantage of mtDNA heteroplasmy, were able to develop gene therapy strategies to target the mtDNA, inducing the increase of the wild-type haplotype. The gene editing tools used by our group and others such as specific endonucleases targeted to the mitochondria, and more recently mitoTALENs and mitochondrial Zinc-Finger Nucleases were shown to effectively shift mtDNA heteroplasmy. This change towards an increase in wild-type mtDNA molecules occurred when the nuclease was specifically designed to cleave DNA regions harboring point mutations or the common deletion. In this chapter we will focus on strategies to target specific mtDNA haplotypes to shift heteroplasmy in vitro and in vivo. A brief overview on heteroplasmic animal models and viral delivery will be introduced, as these will be critical for future translation of this approach into human gene therapy.",
keywords = "DNA editing, Gene therapy, Heteroplasmy, Mitochondrial diseases, mtDNA, TALEN",
author = "Bacman, {Sandra R.} and Pereira, {Claudia V.} and Moraes, {Carlos T}",
year = "2018",
month = "3",
day = "21",
doi = "10.1007/978-3-319-73344-9_24",
language = "English (US)",
isbn = "9783319733432",
pages = "535--563",
booktitle = "Mitochondrial Biology and Experimental Therapeutics",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Targeted mitochondrial genome elimination

AU - Bacman, Sandra R.

AU - Pereira, Claudia V.

AU - Moraes, Carlos T

PY - 2018/3/21

Y1 - 2018/3/21

N2 - Mitochondrial diseases are a heterogeneous group of pathologies, presenting mitochondrial oxidative phosphorylation (OXPHOS) deficiency and subsequent deterioration of affected tissues, usually the ones with high energy demand. Nuclear and mitochondrial DNA (mtDNA) mutations have been associated with mitochondrial disorders, and only palliative therapies are available, with no approach available to correct the underlining genetic problem. Our and other groups, taking advantage of mtDNA heteroplasmy, were able to develop gene therapy strategies to target the mtDNA, inducing the increase of the wild-type haplotype. The gene editing tools used by our group and others such as specific endonucleases targeted to the mitochondria, and more recently mitoTALENs and mitochondrial Zinc-Finger Nucleases were shown to effectively shift mtDNA heteroplasmy. This change towards an increase in wild-type mtDNA molecules occurred when the nuclease was specifically designed to cleave DNA regions harboring point mutations or the common deletion. In this chapter we will focus on strategies to target specific mtDNA haplotypes to shift heteroplasmy in vitro and in vivo. A brief overview on heteroplasmic animal models and viral delivery will be introduced, as these will be critical for future translation of this approach into human gene therapy.

AB - Mitochondrial diseases are a heterogeneous group of pathologies, presenting mitochondrial oxidative phosphorylation (OXPHOS) deficiency and subsequent deterioration of affected tissues, usually the ones with high energy demand. Nuclear and mitochondrial DNA (mtDNA) mutations have been associated with mitochondrial disorders, and only palliative therapies are available, with no approach available to correct the underlining genetic problem. Our and other groups, taking advantage of mtDNA heteroplasmy, were able to develop gene therapy strategies to target the mtDNA, inducing the increase of the wild-type haplotype. The gene editing tools used by our group and others such as specific endonucleases targeted to the mitochondria, and more recently mitoTALENs and mitochondrial Zinc-Finger Nucleases were shown to effectively shift mtDNA heteroplasmy. This change towards an increase in wild-type mtDNA molecules occurred when the nuclease was specifically designed to cleave DNA regions harboring point mutations or the common deletion. In this chapter we will focus on strategies to target specific mtDNA haplotypes to shift heteroplasmy in vitro and in vivo. A brief overview on heteroplasmic animal models and viral delivery will be introduced, as these will be critical for future translation of this approach into human gene therapy.

KW - DNA editing

KW - Gene therapy

KW - Heteroplasmy

KW - Mitochondrial diseases

KW - mtDNA

KW - TALEN

UR - http://www.scopus.com/inward/record.url?scp=85046052788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046052788&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-73344-9_24

DO - 10.1007/978-3-319-73344-9_24

M3 - Chapter

SN - 9783319733432

SP - 535

EP - 563

BT - Mitochondrial Biology and Experimental Therapeutics

PB - Springer International Publishing

ER -